661 related articles for article (PubMed ID: 12525232)
21. The cost-effectiveness of low-dose CT screening for lung cancer: preliminary results of baseline screening.
Wisnivesky JP; Mushlin AI; Sicherman N; Henschke C
Chest; 2003 Aug; 124(2):614-21. PubMed ID: 12907551
[TBL] [Abstract][Full Text] [Related]
22. A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions.
Villanti AC; Jiang Y; Abrams DB; Pyenson BS
PLoS One; 2013; 8(8):e71379. PubMed ID: 23940744
[TBL] [Abstract][Full Text] [Related]
23. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.
Paltiel AD; Walensky RP; Schackman BR; Seage GR; Mercincavage LM; Weinstein MC; Freedberg KA
Ann Intern Med; 2006 Dec; 145(11):797-806. PubMed ID: 17146064
[TBL] [Abstract][Full Text] [Related]
24. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force.
de Koning HJ; Meza R; Plevritis SK; ten Haaf K; Munshi VN; Jeon J; Erdogan SA; Kong CY; Han SS; van Rosmalen J; Choi SE; Pinsky PF; Berrington de Gonzalez A; Berg CD; Black WC; Tammemägi MC; Hazelton WD; Feuer EJ; McMahon PM
Ann Intern Med; 2014 Mar; 160(5):311-20. PubMed ID: 24379002
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness and health impact of lung cancer screening with low-dose computed tomography for never smokers in Japan and the United States: a modelling study.
Kowada A
BMC Pulm Med; 2022 Jan; 22(1):19. PubMed ID: 34996423
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening.
Toumazis I; de Nijs K; Cao P; Bastani M; Munshi V; Ten Haaf K; Jeon J; Gazelle GS; Feuer EJ; de Koning HJ; Meza R; Kong CY; Han SS; Plevritis SK
JAMA Oncol; 2021 Dec; 7(12):1833-1842. PubMed ID: 34673885
[TBL] [Abstract][Full Text] [Related]
27. Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach.
Hofer F; Kauczor HU; Stargardt T
Lung Cancer; 2018 Oct; 124():189-198. PubMed ID: 30268459
[TBL] [Abstract][Full Text] [Related]
28. Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia.
Wade S; Weber M; Caruana M; Kang YJ; Marshall H; Manser R; Vinod S; Rankin N; Fong K; Canfell K
J Thorac Oncol; 2018 Aug; 13(8):1094-1105. PubMed ID: 29689434
[TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of the NHS breast screening programme: life table model.
Pharoah PD; Sewell B; Fitzsimmons D; Bennett HS; Pashayan N
BMJ; 2013 May; 346():f2618. PubMed ID: 23661112
[TBL] [Abstract][Full Text] [Related]
30. Lung cancer screening: review and performance comparison under different risk scenarios.
Tota JE; Ramanakumar AV; Franco EL
Lung; 2014 Feb; 192(1):55-63. PubMed ID: 24153450
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of CT screening in the National Lung Screening Trial.
Black WC; Gareen IF; Soneji SS; Sicks JD; Keeler EB; Aberle DR; Naeim A; Church TR; Silvestri GA; Gorelick J; Gatsonis C;
N Engl J Med; 2014 Nov; 371(19):1793-802. PubMed ID: 25372087
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
Guzauskas GF; Garbett S; Zhou Z; Spencer SJ; Smith HS; Hao J; Hassen D; Snyder SR; Graves JA; Peterson JF; Williams MS; Veenstra DL
JAMA Netw Open; 2020 Oct; 3(10):e2022874. PubMed ID: 33119106
[TBL] [Abstract][Full Text] [Related]
33. An economic evaluation of an abdominal aortic aneurysm screening program in Italy.
Giardina S; Pane B; Spinella G; Cafueri G; Corbo M; Brasseur P; Orengo G; Palombo D
J Vasc Surg; 2011 Oct; 54(4):938-46. PubMed ID: 21820837
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness of Treatment Thresholds for Subsolid Pulmonary Nodules in CT Lung Cancer Screening.
Hammer MM; Eckel AL; Palazzo LL; Kong CY
Radiology; 2021 Sep; 300(3):586-593. PubMed ID: 34128723
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study.
Du Y; Sidorenkov G; Heuvelmans MA; Groen HJM; Vermeulen KM; Greuter MJW; de Bock GH
Eur J Cancer; 2020 Aug; 135():121-129. PubMed ID: 32563896
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of population screening for alpha-1 antitrypsin deficiency: a decision analysis.
Shermock KM; Gildea TR; Singer M; Stoller JK
COPD; 2005 Dec; 2(4):411-8. PubMed ID: 17147006
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of different screening strategies for abdominal aortic aneurysm.
Wanhainen A; Lundkvist J; Bergqvist D; Björck M
J Vasc Surg; 2005 May; 41(5):741-51; discussion 751. PubMed ID: 15886653
[TBL] [Abstract][Full Text] [Related]
38. Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis.
Danese MD; Powe NR; Sawin CT; Ladenson PW
JAMA; 1996 Jul 24-31; 276(4):285-92. PubMed ID: 8656540
[TBL] [Abstract][Full Text] [Related]
39. Cost-Effectiveness of Screening for Intermediate Age-Related Macular Degeneration during Diabetic Retinopathy Screening.
Chan CK; Gangwani RA; McGhee SM; Lian J; Wong DS
Ophthalmology; 2015 Nov; 122(11):2278-85. PubMed ID: 26315045
[TBL] [Abstract][Full Text] [Related]
40. Potential cost-effectiveness of one-time screening for lung cancer (LC) in a high risk cohort.
Marshall D; Simpson KN; Earle CC; Chu C
Lung Cancer; 2001 Jun; 32(3):227-36. PubMed ID: 11390004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
